SCHEMBL1852264

SCHEMBL1852264

FC(F)(F)c1cccc(-c2ccc3scnc3c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.46
RIPK2 O43353 4/20 0.44
TRPV3 Q8NET8 1/20 0.41
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
PIK3CD O00329 1/20 0.39
COMT P21964 1/20 0.39
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NOTUM Q6P988 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA3 P34903 1/20 0.37
IDH1 O75874 2/20 0.37
IDH2 P48735 1/20 0.37
RIPK3 Q9Y572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3308095 0.75 PIK3CA (0.53) TGFBR1RIPK2ALOX5APFEN1PIK3CD
SCHEMBL3308104 0.73 KIF11 (0.43) TGFBR1RIPK2TRPV3ALOX5APFEN1
SCHEMBL3303277 0.73 RIPK2 (0.39) TGFBR1RIPK2TRPV3ALOX5APFEN1
SCHEMBL28048502 0.73 ALDH1A1 (0.54) TGFBR1RIPK2ALOX5APFEN1PIK3CD
SCHEMBL27110095 0.72 CLK1 (0.61) IDH2
SCHEMBL30847290 0.72 CLK1 (0.61) IDH2
SCHEMBL5224565 0.71 RIPK2 (0.49) TGFBR1RIPK2KDR
SCHEMBL20351900 0.70 TRPV3 (0.42) TGFBR1RIPK2TRPV3ALOX5APFEN1
SCHEMBL24093862 0.70 CNR1 (0.48) TGFBR1RIPK2TRPV3KDR
SCHEMBL13394458 0.70 MAP4K4 (0.49) TGFBR1RIPK2ALDH1A1HSD17B10RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
US-8420052-B2 Imaging agents useful for identifying AD pathology SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-04-16 US disclosed
EP-2323697-A2 IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY Siemens Medical Solutions USA, Inc. (US) 2011-05-25 EP disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology SIEMENS MEDICAL SOLUTIONS USA, INC. 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098634-A1 Imaging Agents Useful for Identifying AD Pathology APP, APBA1, PYGB TGFBR1 3903/4885RIPK2 4447/4885TRPV3 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.